Deliberazione - 3 - 09/01/2025

Autorizzazione allo studio clinico sperimentale, farmacologico, profit, denominato: “A Phase 3, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connective tissue disease (CTD)” - Codice Protocollo 221672